Overview:

Targeted and immunologic therapies are continuing to transform the treatment landscape for patients with small cell lung cancer (SCLC) across all disease settings. In recent years, the characterization of novel treatment approaches has led fundamental shifts in how these tumors are managed, and therapies directed against new targets have shown substantial activity.

This Community Oncology Connections™ program is a series of live, online meetings focused on providing community oncologists with the latest updates to the management of SCLC, offering participants an opportunity to participate in discussion of novel approaches to maintenance therapy, immunotherapy, and the emerging role of novel targeted therapies across the treatment landscape.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Discuss current trial data describing novel strategies for the management of limited- and extensive-stage SCLC
• Plan strategies to prevent and proactively manage treatment-related adverse events in patients with SCLC
• Apply clinical trial evidence supporting the efficacy and safety of SCLC treatment strategies to optimally manage patients with SCLC in the second- and subsequent-line setting

Target Audience:

This educational program is primarily directed toward community-based oncologists involved in the treatment of SCLC.

Accreditation/Credit Designation:

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour. 

Acknowledgment of Educational Support

This activity is supported by educational grants from Daiichi Sankyo, Inc.; Merck Sharp & Dohme, LLC; Amgen Inc.

Have a question for the PER® team?

Email: info@gotoper.com